CTOs on the Move

BioMotiv

www.biomotiv.com

 
BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.biomotiv.com
  • 20600, Chagrin Boulevard
    Shaker Heights, OH USA 44122
  • Phone: 216.455.3216

Executives

Name Title Contact Details

Similar Companies

Pfenex

We are a clinical stage development and licensing biotechnology company focused on leveraging our Pfenex Expression Technology™ platform to develop and improve protein therapies for unmet patient needs.

CELLINK

CELLINK is the first bioink company revolutionizing bioprinting. Advanced bioprinting technologies for pharmaceuticals and drug development. CELLINK is pioneering cell cultivation systems through bioprinting, analysis and liquid handling or bioprocessing.

ImmunoPrecise Antibodies

IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry`s most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal — is to improve the specificity of biotherapeutics by unlocking the language of the genome.

Texcell NA

Texcell NA is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aqualung Therapeutics

Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension.